logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Loxapine inhalation (Staccato Loxapine) for agitation associated with schizophrenia or bipolar-1 disorder

< Back

Loxapine inhalation (Staccato Loxapine) for agitation associated with schizophrenia or bipolar-1 disorder

Drugs

Mental Health, Drug Abuse and Learning Difficulties

August 2010


Loxapine inhalation (Staccato loxapine, AZ-004) is a breath-actuated hand-held disposable inhaler (the Staccato system a) which delivers a single dose of loxapine. Loxapine is a dopamine-2 and serotonin-2a receptor antagonist which acts as a tranquiliser. The exact mechanism of action of loxapine has not been established. Loxapine inhalation is intended to rapidly treat acute agitation as a substitute for currently available parenteral or oral therapies. Loxapine is administered as needed at 5mg or 10mg, up to 3 doses in a 24 hour period.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

PDF Report



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts